Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 4/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.46 |
| ▸ | CDK4 | P11802 | 3/20 | 0.44 |
| ▸ | CCND1 | P24385 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8430621 | 0.90 | KMO (0.62) | KMOHTR7ACLYKCNA3MCL1 | |
| SCHEMBL18856955 | 0.87 | HTR2A (0.56) | KMOHTR7ACLYKCNA3MCL1 | |
| SCHEMBL9995332 | 0.83 | KMO (0.59) | KMOHTR7ACLYMCL1CDK4 | |
| SCHEMBL10311228 | 0.82 | KMO (0.57) | KMOHTR7ACLYKCNA3MCL1 | |
| SCHEMBL18856947 | 0.82 | HTR2A (0.55) | KMOHTR7ACLYKCNA3CDK4 | |
| SCHEMBL4651648 | 0.80 | KDM4E (0.53) | KMOMCL1CDK4CCND1HTR2A | |
| SCHEMBL8434667 | 0.80 | HTR2C (0.56) | HTR7CDK4CCND1HTR2AHTR2C | |
| SCHEMBL19526836 | 0.80 | HTR7 (0.57) | KMOHTR7MCL1CDK4CCND1 | |
| SCHEMBL27812843 | 0.80 | CDK4 (0.44) | MCL1CDK4CCND1HTR2AHTR2C | |
| SCHEMBL4943951 | 0.78 | SCN9A (0.45) | ACLYCDK4CCND1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | KMO 342/4885HTR7 14/4885ACLY 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.